An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Someone online asked whether people taking GLP‑1 drugs (the class that includes medicines like Ozempic and Wegovy) not only lose weight but also seem to lose other cravings — for example for alcohol — and whether they might even become less glued to their phones. That’s the basic question: are people noticing reduced addictive behaviors while on these medications? GLP‑1 refers to a naturally occurring hormone (glucagon‑like peptide‑1) that helps control appetite and blood sugar. The medicines called GLP‑1 receptor agonists are drugs that mimic that hormone. They slow how fast your stomach empties, make you feel fuller sooner, and change signals between your gut and brain that reduce hunger. They were developed for diabetes and obesity, and many people now use them under brand names like Ozempic or Wegovy. What the reports and early studies suggest is mixed and mostly preliminary. There are convincing lab and animal studies showing GLP‑1 drugs can change brain reward circuits that are involved in addiction-like behaviors. Some human reports and small studies have noticed reduced alcohol intake or less interest in rewarding foods while people are on these drugs. But most of that evidence is anecdotal (individual reports) or from small, short-term studies. There’s very little rigorous research specifically looking at things like smartphone overuse or behavioral addictions, so we don’t have good data to say these drugs reduce screen time or compulsive checking. Why people are interested is easy to understand: if a medication that reduces appetite also dampens other cravings, it could help people with problematic alcohol use, smoking, or other compulsive habits. That would be a big deal because behavioral addictions are common and hard to treat. For now, the most plausible takeaway is that some people do notice changes in what they find rewarding or tempting while on GLP‑1 drugs, but effects probably vary a lot between individuals and behaviors. Important cautions: these drugs are prescription medicines with side effects (nausea, stomach issues, possible gallbladder or pancreas concerns) and are approved for diabetes and weight management, not as general “anti‑addiction” pills. We don’t know long‑term effects on the brain’s reward system, and using them specifically to treat addiction hasn’t been proven or approved. If someone is struggling with alcohol or other addictive behaviors, evidence‑based treatments and a clinician’s advice are the right first steps. Bottom line: there are hints GLP‑1 drugs can blunt some reward‑driven behaviors, but it’s early, not guaranteed, and not a substitute for established addiction care.
Source: r/Semaglutide